These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1504 related items for PubMed ID: 28747274

  • 1. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L, ANRS IPERGAY Study Group.
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [Abstract] [Full Text] [Related]

  • 2. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM, ANRS IPERGAY study group.
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [Abstract] [Full Text] [Related]

  • 3. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG, PrEP Brasil Study Team.
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [Abstract] [Full Text] [Related]

  • 4. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac C, Chas J, Meyer L, Molina JM, Spire B, ANRS IPERGAY Study Group.
    AIDS Care; 2016 Mar; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [Abstract] [Full Text] [Related]

  • 5. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D, ANRS PREVENIR Study Group.
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K.
    Lancet HIV; 2024 Aug; 11(8):e508-e521. PubMed ID: 39008999
    [Abstract] [Full Text] [Related]

  • 7. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB.
    Lancet; 2020 Jul 25; 396(10246):239-254. PubMed ID: 32711800
    [Abstract] [Full Text] [Related]

  • 8. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM, iPrEx investigators.
    Lancet HIV; 2015 Dec 25; 2(12):e512-9. PubMed ID: 26614965
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, DISCOVER study team.
    Lancet HIV; 2021 Jul 25; 8(7):e397-e407. PubMed ID: 34197772
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
    Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team.
    Lancet HIV; 2023 Dec 25; 10(12):e767-e778. PubMed ID: 37952550
    [Abstract] [Full Text] [Related]

  • 11. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM.
    AIDS; 2018 Sep 24; 32(15):2161-2169. PubMed ID: 30212403
    [Abstract] [Full Text] [Related]

  • 12. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, Tee BK, Fairley CK, Chang CC, Armishaw J, Vujovic O, Penn M, Cundill P, Forgan-Smith G, Gall J, Pickett C, Lal L, Mak A, Spelman TD, Nguyen L, Murphy DA, Ryan KE, El-Hayek C, West M, Ruth S, Batrouney C, Lockwood JT, Hoy JF, Hellard ME, Stoové MA, Wright EJ, PrEPX Study Team.
    JAMA; 2019 Apr 09; 321(14):1380-1390. PubMed ID: 30964528
    [Abstract] [Full Text] [Related]

  • 13. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
    Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L, ANRS IPERGAY Study Group.
    Lancet Infect Dis; 2018 Mar 09; 18(3):308-317. PubMed ID: 29229440
    [Abstract] [Full Text] [Related]

  • 14. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON.
    Lancet; 2016 Jan 02; 387(10013):53-60. PubMed ID: 26364263
    [Abstract] [Full Text] [Related]

  • 15. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA.
    JAMA Intern Med; 2016 Jan 02; 176(1):75-84. PubMed ID: 26571482
    [Abstract] [Full Text] [Related]

  • 16. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
    Laurent C, Dembélé Keita B, Yaya I, Le Guicher G, Sagaon-Teyssier L, Agboyibor MK, Coulibaly A, Traoré I, Malan JB, De Baetselier I, Eubanks A, Riegel L, Rojas Castro D, Fayé-Ketté H, Koné A, Diandé S, Dagnra CA, Serrano L, Diallo F, Mensah E, Dah TTE, Anoma C, Vuylsteke B, Spire B, CohMSM-PrEP Study Group.
    Lancet HIV; 2021 Jul 02; 8(7):e420-e428. PubMed ID: 34048794
    [Abstract] [Full Text] [Related]

  • 17. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
    Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM.
    Lancet Infect Dis; 2014 Jun 02; 14(6):468-75. PubMed ID: 24613084
    [Abstract] [Full Text] [Related]

  • 18. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
    Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, van Duijnhoven YTHP, Bruisten S, Oostvogel P, Davidovich U, Hogewoning A, Prins M, de Vries HJC, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam (H-TEAM) Initiative.
    Lancet HIV; 2019 Jul 02; 6(7):e447-e455. PubMed ID: 31178284
    [Abstract] [Full Text] [Related]

  • 19. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team.
    Lancet Infect Dis; 2014 Nov 02; 14(11):1055-1064. PubMed ID: 25300863
    [Abstract] [Full Text] [Related]

  • 20. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, Pidwell T, Mendel E, Fynn L, Jones K, Wiesner L, Slack C, Strode A, Spiegel H, Hosek S, Rooney J, Gray G, Bekker LG.
    Lancet Child Adolesc Health; 2020 Dec 02; 4(12):875-883. PubMed ID: 33222803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.